Clinical Trial Update: Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating melphalan flufenamide (melflufen) plus dexamethasone with bortezomib or daratumumab in relapsed/refractory multiple myeloma; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Daratumumab (daratumumab)
• Dex
• melphalan flufenamide (melphalan flufenamide)

Snippet

Sponsor: Oncopeptides AB | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-12-19